Genentech’s blood cancer drug Polivy earned an accelerated approval from the U.S. FDA due to the complete response rate shown during clinical trials. This marks the fifth blood cancer drug approved for Genentech. Polivy, which was also granted Breakthrough Therapy designation, uses ADC technology developed by Seattle Genetics and licensed to Genentech. The FDA’s Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. Polivy was approved two months ahead of its August PDUFA date. However, the FDA noted that further clinical trials are required. Learn More